原发性肾细胞癌立体定向消融放疗后长期肾功能结局:包括孤立肾患者——国际肾脏放射外科肿瘤学联盟报告
国际多中心研究纳入190例接受SABR的原发性肾细胞癌患者(其中孤立肾56例),中位随访5.0年。孤立肾与双侧肾患者SABR后5年eGFR下降程度及透析率无显著差异,肿瘤大小和基线eGFR是长期肾功能下降的主要预测因素。
要点
- 孤立肾与双侧肾患者SABR后5年eGFR下降程度无显著差异
- SABR后透析率低,孤立肾组3.6% vs 双侧肾组3.7%
- 肿瘤每增大1 cm及基线eGFR每升高10 ml/min与1年eGFR下降≥15 ml/min相关
核心结论
- SABR长期随访后肾功能下降程度中等,孤立肾与双侧肾患者之间无显著差异。
- 肿瘤大小和基线eGFR是预测长期肾功能下降的主要因素。
研究设计与样本
- 国际多中心研究,纳入12家国际肾脏放射外科联盟机构中接受SABR治疗的原发性肾细胞癌且随访≥2年的患者,共190例(孤立肾56例)。
- 肾功能以估算肾小球滤过率(eGFR)测量,中位随访5.0年(四分位距3.4-6.8年)。
主要发现
- 孤立肾组 vs 双侧肾组SABR前eGFR均值分别为61.1(标准差23.2)ml/min vs 58.0(标准差22.3)ml/min(p=0.32)。
- 孤立肾组 vs 双侧肾组中位肿瘤大小分别为3.65 cm(四分位距2.59-4.50 cm)vs 4.00 cm(四分位距3.00-5.00 cm)(p=0.026)。
- SABR后5年,孤立肾组 vs 双侧肾组eGFR分别下降-14.5(标准差7.6)ml/min vs -13.3(标准差15.9)ml/min(p=0.67)。
- SABR后透析率:孤立肾组3.6%(n=2/56) vs 双侧肾组3.7%(n=5/134)。
- 多变量分析显示,肿瘤每增大1 cm(OR 1.57;95%CI 1.14-2.16,p=0.0055)和基线eGFR每升高10 ml/min(OR 1.30;95%CI 1.02-1.66,p=0.034)与1年时eGFR下降≥15 ml/min相关。
临床怎么用
- 原文结论认为SABR是局限性肾细胞癌患者有前景的无创、保留肾单位的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Renal function preservation is particularly important following nonoperative treatment of localized renal cell carcinoma (RCC) since patients are often older with medical comorbidities. Our objective was to report long-term renal function outcomes after stereotactic ablative radiotherapy (SABR) including patients with a solitary kidney. METHODS: Patients with primary RCC treated with SABR with ≥2 yr of follow-up at 12 International Radiosurgery Consortium for Kidney institutions were included. Renal function was measured by estimated glomerular filtration rate (eGFR). KEY FINDINGS AND LIMITATIONS: In total, 190 patients (56 with a solitary kidney) underwent SABR and were followed for a median of 5.0 yr (interquartile range [IQR]: 3.4-6.8). In patients with a solitary kidney versus bilateral kidneys, pre-SABR eGFR (mean [standard deviation]) was 61.1 (23.2) versus 58.0 (22.3) ml/min (p = 0.32) and the median tumor size was 3.65 cm (IQR: 2.59-4.50 cm) versus 4.00 cm (IQR: 3.00-5.00 cm; p = 0.026). At 5 yr after SABR, eGFR decreased by -14.5 (7.6) and -13.3 (15.9) ml/min (p = 0.67), respectively, and there were similar rates of post-SABR dialysis (3.6% [n = 2/56] vs 3.7% [n = 5/134]). A multivariable analysis demonstrated that increasing tumor size (odds ratio [OR] per 1 cm: 1.57; 95% confidence interval [CI]: 1.14-2.16, p = 0.0055) and baseline eGFR (OR per 10 ml/min: 1.30; 95% CI: 1.02-1.66, p = 0.034) were associated with an eGFR decline of ≥15 ml/min at 1 yr. CONCLUSIONS AND CLINICAL IMPLICATIONS: With long-term follow-up after SABR, kidney function decline remains moderate, with no observed difference between patients with a solitary kidney and bilateral kidneys. Tumor size and baseline eGFR are dominant factors predictive of long-term renal function decline. PATIENT SUMMARY: With long-term follow-up, stereotactic ablative radiotherapy (SABR) yields moderate long-term renal function decline and low dialysis rates even in patients with a solitary kidney. SABR thus represents a promising noninvasive, nephron-sparing option for patients with localized renal cell carcinoma.
引用
- Tan VS, Correa RJM, Warner A, et al. Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney. Eur Urol Oncol. 2024. PMID: 38987159. doi:10.1016/j.euo.2024.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。